Skip to main content
Biophytis S.A. logo

Biophytis S.A. — Investor Relations & Filings

Ticker · ALBPS ISIN · FR001400OLP5 LEI · 9695008GIE061NBGU106 PA Professional, scientific and technical activities
Open in API
Filings indexed 546 across all filing types
Latest filing 2024-04-19 Capital/Financing Update
Country FR France
Listing PA ALBPS

About Biophytis S.A.

https://www.biophytis.com/en/

Biophytis S.A. is a clinical-stage biotechnology company focused on developing therapeutics to slow degenerative processes associated with aging and improve longevity. The company's primary strategy is centered on treating diseases that impair mobility. Its lead drug candidate, BIO101, is being advanced in late-stage clinical development for multiple age-related conditions. A key program is the SARA Phase 3 trial, the first-ever pivotal study for the treatment of sarcopenia (age-related muscle loss). Additionally, BIO101 is being evaluated in the OBA Phase 2 clinical trial for addressing muscle wasting in patients with obesity. The company aims to preserve muscle function and enhance functional outcomes for patients.

Recent filings

Filing Released Lang Actions
Biophytis annonce un changement de ratio pour son programme d'American Depositary Receipt (
Capital/Financing Update Classification · 98% confidence The document is a press release from Biophytis announcing a change in the ratio of its American Depositary Receipts (ADRs) relative to its ordinary shares (a reverse split/consolidation of ADS). This action directly impacts the company's capital structure and the trading mechanism of its securities on the Nasdaq. This type of announcement, dealing with fundraising, financing activities, or capital structure changes, aligns best with the 'Capital/Financing Update' category. It is not an Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or a specific regulatory filing like DIRS or DIV. Since it is a formal announcement detailing a structural change related to capital, 'CAP' is the most appropriate classification.
2024-04-19 French
Biophytis announces new Scientific Advisory Board for its phase 2 OBA clinical study in obesity
Regulatory Filings Classification · 85% confidence The document is explicitly titled "Press release" and announces the formation of a new Scientific Advisory Board and plans to file an IND application with the FDA. This type of announcement, which details operational updates, strategic appointments, and upcoming regulatory steps, does not fit neatly into the specific financial reporting categories (like 10-K, IR, ER, or DIV). It is a general corporate update. Since it is not a formal regulatory filing like a 20-F or 6-K (which would typically be classified as RNS if short, or potentially LTR if legal), and it doesn't fit any other specific category (like MANG for board changes, or CAP for financing), the most appropriate fallback category for a general, non-financial-result-focused corporate announcement is Regulatory Filings (RNS), as it serves as a general announcement mechanism for material, non-standardized news.
2024-04-18 English
Biophytis annonce la création d'un Conseil Scientifique pour son étude clinique de phase 2 OBA dans l'obésité
Regulatory Filings Classification · 95% confidence The document is explicitly titled "Communiqué de presse" (Press Release) and announces specific corporate news: the creation of a Scientific Advisory Board (SAB) for a Phase 2 clinical study (OBA) and the upcoming filing of an Investigational New Drug (IND) application with the FDA. This type of announcement, detailing operational and scientific progress rather than comprehensive financial results (like 10-K or IR) or management changes (MANG), typically falls under a general regulatory announcement or a specific press release category. Since it is not a full financial report, an earnings release, or a specific filing like DIRS or DIV, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as a deck, but the format suggests a standard press release. Given the options, RNS serves as the best general regulatory announcement fallback for non-standard, material news releases that aren't explicitly covered elsewhere. The length (7806 chars) is substantial, indicating it is the primary content, not just a brief announcement of a report (ruling 2 does not apply).
2024-04-18 French
Biophytis files a patent application and strengthens its intellectual property in obesity
Regulatory Filings Classification · 92% confidence The document is explicitly titled "Press release" and announces a specific corporate action: "Biophytis files a patent application and strengthens its intellectual property in obesity." This is a material, non-financial update concerning intellectual property and R&D strategy, disseminated via a press release format. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). Since the core subject is a strategic corporate announcement (patent filing), and it does not fit the specific categories like DIRS, MANG, or DIV, the most appropriate general category for significant, non-standard corporate news disseminated via press release is Regulatory Filings (RNS), which serves as a broad category for important announcements not covered elsewhere, or potentially Investor Presentation (IP) if it were a presentation, but here it is a news announcement. Given the nature of announcing a patent filing, which is a key piece of corporate information, RNS is the best fit as a general regulatory/corporate announcement fallback, although it is not a standard SEC form. If a more specific category existed for IP updates, that would be chosen. Based on the provided definitions, RNS is the most suitable catch-all for significant, non-financial press releases.
2024-04-15 English
Biophytis dépose une demande de brevet et renforce sa propriété intellectuelle dans l’obésité
Regulatory Filings Classification · 100% confidence The document is titled "Communiqué de presse" (Press Release) and announces a specific corporate action: the filing of a patent application related to obesity treatment. This is a material, non-periodic announcement concerning intellectual property and business strategy. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a proxy statement (DEF 14A). While it relates to the company's assets, it is a specific announcement rather than a general governance report (CGR) or a general regulatory filing (RNS). Since the core topic is the strengthening of intellectual property (patent filing), it best fits under a category related to corporate actions or specific announcements that aren't covered by the primary financial reports. Given the options, this type of specific, material corporate news release that doesn't fit neatly into the defined financial reporting categories (like 10-K, ER, IR) is often classified as a general Regulatory Filing (RNS) or, if the focus is on a specific corporate event like M&A or financing, those codes would apply. Since this is an IP/Patent announcement, and there is no specific 'IP Filing' code, RNS (Regulatory Filings - general fallback) is the most appropriate general category for a press release announcing a specific, non-financial regulatory/legal event, although it is a very specific type of announcement. However, looking closely at the definitions, none perfectly capture 'Patent Filing Announcement'. It is a press release announcing a corporate development. RNS is the fallback for miscellaneous filings. Given the context of a press release announcing a strategic IP move, RNS is the best fit among the provided codes as a general regulatory/corporate announcement.
2024-04-15 French
Biophytis announces its 2023 financial results and provides an update on its business activities
Earnings Release Classification · 95% confidence The document is a press release titled 'Biophytis announces its 2023 financial results and provides an update on its business activities'. It summarizes key financial highlights, operational updates, and includes condensed financial tables (income statement and balance sheet). While it contains financial data, it is structured as an initial announcement of results rather than the full audited Annual Report (10-K) or a comprehensive Interim Report (IR). According to the filing definitions, an Earnings Release (ER) is the initial announcement of quarterly/periodical financial results containing key highlights, which perfectly matches this document's content and purpose. FY 2023
2024-04-08 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.